Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

The deal provides SanegeneBio with an upfront payment of $200m.

Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...